OR WAIT null SECS
The COVID-19 pandemic has led to many changes in how pharmaceutical companies develop vaccines.
More technologies and treatments are emerging for COVID-19—along with new variants.
Partnerships formed during the COVID-19 pandemic have provided a platform for change in assay development and transfers.
July 08, 2021
Exscientia has been given funding from the COVID-19 Therapeutics Accelerator to accelerate the optimization of a new class of COVID-19 drugs created using its AI drug design platform.
The approved changes to the API manufacturing plant in Leiden, the Netherlands will enable an increase in API capacity.
July 07, 2021
An additional batch of the Janssen COVID-19 vaccine has been authorized by FDA under the Emergency Use Authorization.
July 06, 2021
The rise of COVID variants has made public health officials anxious to expand immunity more widely and quickly in areas with low vaccination rates, and experts hope that full approval of existing and new vaccines will increase public confidence in their value.
July 03, 2021
Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.
July 02, 2021
Despite some improved understanding of adapted processes in light of the pandemic, information is still not filtered throughout the qualified persons community fully and more work by authorities and associations is required to improve communications.
Vaccines define the path to putting the pandemic in the rear-view mirror.
Five therapeutic candidates for the treatment of COVID-19 are identified as promising by the European Commission.
July 01, 2021
The first participants, both previously vaccinated and unvaccinated, receive AstraZeneca’s new COVID-19 variant vaccine AZD2816.
With COVID-19 vaccine facilities receiving recent citations, it is evident that failure to meet cleaning and sanitization requirements puts patients, facilities, and operators at risk.